A Engert

COLLECTION, AUTOMATED PROCESSING AND DISSEMINATION OF REAL-TIME TRAFFIC INFORMATION. GERMAN AUTOMOBILE CLUB: ADAC

A Engert, 1997 .

A dominant linear B‐cell epitope of ricin A‐chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti‐CD25 immunotoxin

A Engert, R. Schnell, G. Fracasso, 2004, Clinical and experimental immunology.

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.

A Engert, G. Schwarzer, J. Bohlius, 2008, The Cochrane database of systematic reviews.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

M Sieber, A Engert, H. Eich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.

W Hiddemann, A Engert, M. Tiemann, 1996, Leukemia.